4basebio PLC (AIM:4BB)

Market Cap	75.07M -47.9%
Revenue (ttm)	1.69M +81.5%
Net Income	-16.91M
EPS	-1.09
Shares Out	15.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	573
Open	462.20
Previous Close	485.00
Day's Range	450.00 - 520.00
52-Week Range	420.00 - 1,150.00
Beta	0.87
Analysts	Buy
Price Target	1,700.00 (+277.78%)
Earnings Date	May 22, 2026

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccine...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 110
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: 4BB

Financial Performance

In 2025, 4basebio's revenue was 1.69 million, an increase of 81.46% compared to the previous year's 933,000. Losses were -16.91 million, 37.1% more than in 2024.